Literature DB >> 22076564

Recurrences after surgical resection of intraductal papillary mucinous neoplasm of the pancreas: a single-center study of recurrence predictive factors.

Guillaume Passot1, Roger Lebeau, Valérie Hervieu, Thierry Ponchon, Franck Pilleul, Mustapha Adham.   

Abstract

OBJECTIVE: The detection of intraductal papillary mucinous neoplasms (IPMN) has increased over the last decade, but still, management remains controversial. The main problems are their potential for malignancy and risk of recurrence. The purpose of this study was to determine the predictive factors of recurrence after surgical resection.
METHODS: All patients with IPMN who underwent pancreatectomy with curative intent were considered. Data were collected from a prospective base.
RESULTS: From 1994 to 2009, 104 patients underwent pancreatectomy. Twenty-one (20%) had recurrence, 15 on remnant pancreas (none on pancreatic cut surface) and 6 with distant metastases. Twelve patients had total pancreatectomy (1 awaiting surgery). Thirteen (38.2%) of 34 patients with invasive IPMN and 20 (25.9%) of 77 with main duct involvement (including combined type) had recurrence. In univariate analysis, American Society of Anesthesiologist score and histological and duct type had a significant impact on recurrence rate. In multivariate analysis, histological type (invasiveness) was the only significant predictive factor for recurrence.
CONCLUSION: The risk of recurrence of IPMN after resection depends on the histological type. According to surgical margin, invasiveness, and the type of duct involved, we identified a high-risk group with invasive main duct lesion and a low-risk group with noninvasive branch duct lesion.

Entities:  

Mesh:

Year:  2012        PMID: 22076564     DOI: 10.1097/MPA.0b013e318222bc9c

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  12 in total

1.  Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.

Authors:  Antonio Pea; Jun Yu; Neda Rezaee; Claudio Luchini; Jin He; Marco Dal Molin; James F Griffin; Helen Fedor; Shahriar Fesharakizadeh; Roberto Salvia; Matthew J Weiss; Claudio Bassi; John L Cameron; Lei Zheng; Aldo Scarpa; Ralph H Hruban; Anne Marie Lennon; Michael Goggins; Christopher L Wolfgang; Laura D Wood
Journal:  Ann Surg       Date:  2017-07       Impact factor: 12.969

2.  Intraductal tubulopapillary neoplasm of the pancreas with somatic BRAF mutation.

Authors:  Takahiro Urata; Yoshiki Naito; Michiko Nagamine; Yoshihiro Izumi; Ginga Tonaki; Hajime Iwasaki; Akiko Sasaki; Akira Yamasaki; Nobuhiro Minami; Rituko Yoshioka; Hideki Kitada; Yoshi Takekuma; Hiroshi Yokomizo; Seiji Fukuda; Hiroshi Yamaguchi; Yuko Kuboki; Toru Furukawa; Michio Hifumi
Journal:  Clin J Gastroenterol       Date:  2012-11-15

3.  Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma.

Authors:  Neda Rezaee; Carlotta Barbon; Ahmed Zaki; Jin He; Bulent Salman; Ralph H Hruban; John L Cameron; Joseph M Herman; Nita Ahuja; Anne Marie Lennon; Matthew J Weiss; Laura D Wood; Christopher L Wolfgang
Journal:  HPB (Oxford)       Date:  2015-12-10       Impact factor: 3.647

4.  The Dilemma of the Dilated Main Pancreatic Duct in the Distal Pancreatic Remnant After Proximal Pancreatectomy for IPMN.

Authors:  Rachel E Simpson; Eugene P Ceppa; Howard H Wu; Fatih Akisik; Michael G House; Nicholas J Zyromski; Attila Nakeeb; Mohammad A Al-Haddad; John M DeWitt; Stuart Sherman; C Max Schmidt
Journal:  J Gastrointest Surg       Date:  2019-01-02       Impact factor: 3.452

5.  Recurrence of non-invasive intraductal papillary municious neoplasm seven years following total pancreatectomy.

Authors:  Nayima M Clermont Dejean; Sinziana Dumitra; Jeffrey S Barkun
Journal:  Int J Surg Case Rep       Date:  2013-05-28

Review 6.  ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts.

Authors:  Grace H Elta; Brintha K Enestvedt; Bryan G Sauer; Anne Marie Lennon
Journal:  Am J Gastroenterol       Date:  2018-02-27       Impact factor: 10.864

7.  Subtype of intraductal papillary mucinous neoplasm of the pancreas is important to the development of metachronous high-risk lesions after pancreatectomy.

Authors:  Ji Eun Kwon; Kee-Taek Jang; Youngju Ryu; Naru Kim; Sang Hyun Shin; Jin Seok Heo; Dong Wook Choi; In Woong Han
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2019-11-29

8.  Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decision-making programme using decision tables.

Authors:  Lianne Scholten; Anouk Ej Latenstein; Cora M Aalfs; Marco J Bruno; Olivier R Busch; Bert A Bonsing; Bas Groot Koerkamp; I Quintus Molenaar; Dirk T Ubbink; Jeanin E van Hooft; Paul Fockens; Jolanda Glas; J Hans DeVries; Marc G Besselink
Journal:  United European Gastroenterol J       Date:  2020-07-23       Impact factor: 4.623

9.  Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Intraductal Papillary Mucinous Neoplasm (IPMN).

Authors:  Yoshiki Fujiyama; Yusuke Kumamoto; Nobuyuki Nishizawa; Shuji Nakamoto; Hiroki Harada; Kazuko Yokota; Yoko Tanaka; Kazuharu Igarashi; Hironobu Oiki; Kosuke Okuwaki; Tomohisa Iwai; Sabine Kajita; Hiroyuki Takahashi; Hiroshi Tajima; Takashi Kaizu; Jiichiro Sasaki; Masahiko Watanabe; Keishi Yamashita
Journal:  Ann Surg Oncol       Date:  2020-03-06       Impact factor: 5.344

Review 10.  Intraductal Papillary Mucinous Adenocarcinoma of the Pancreas: Clinical Outcomes, Prognostic Factors, and the Role of Adjuvant Therapy.

Authors:  Zhi Ven Fong; Carlos Fernández-Del Castillo
Journal:  Viszeralmedizin       Date:  2015-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.